Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib and SRT for EGFR+ NSCLC Brain Metastases
NCT04519983Phase 2Unknown
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04519983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519983.